Aging Clin Exp Res 2020 Feb 01
Prognostic value of non-alcoholic fatty liver disease in the elderly patients.
Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome, a risk factor for mortality and cardiovascular morbidity, ...
Read More
Source: PubMed
J. Nutr. Biochem.
Maternal diets enriched in olive oil regulate lipid metabolism and levels of PPARs and their coactivators in the fetal liver in a rat model of gestational diabetes mellitus.
Fornes D, Gomez Ribot D, Heinecke F, Roberti SL, Capobianco E, Jawerbaum A
In a rat model of gestational diabetes mellitus (GDM) programmed in the offspring of neonatal streptozotocin-induced (nSTZ) diabetic rats, lipids are ...
Read More
Source: PubMed
Wiad. Lek.
Associations of irs-1 polymorphism with various components of the metabolic syndrome in hypertensive patients
Kochuieva M, Psarova V, Ruban L, Kyrychenko N, Alypova O, Matlai O, Shalimova A
The metabolic syndrome is one of the most discussed cross-disciplinary problems of modern medicine. Now there are various definitions and criteria of ...
Read More
Source: PubMed
Sci Transl Med
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
Wolska A, Lo L, Sviridov DO, Pourmousa M, Pryor M, Ghosh SS, Kakkar R, Davidson M, Wilson S, Pastor RW, Goldberg IJ, Basu D, Drake SK, Cougnoux A, Wu MJ, Neher SB, Freeman LA, Tang J, Amar M, Devalaraja M, Remaley AT
Recent genetic studies have established that hypertriglyceridemia (HTG) is causally related to cardiovascular disease, making it an active area for dr ...
Read More
Source: PubMed
Cas. Lek. Cesk.
Management of metabolic adverse effects of everolimus in patients with renal carcinoma.
Gregorová J, Holecková P, Žáková K
Everolimus is administered to patients with metastatic renal cell carcinoma in full daily dose of 10 mg or in reduced daily dose of 5 mg in case adver ...
Read More
Source: PubMed
Aging Clin Exp Res 2020 Feb 01
Prognostic value of non-alcoholic fatty liver disease in the elderly patients.
Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome, a risk factor for mortality and cardiovascular morbidity, ...
Read More
Source: PubMed
J. Nutr. Biochem.
Maternal diets enriched in olive oil regulate lipid metabolism and levels of PPARs and their coactivators in the fetal liver in a rat model of gestational diabetes mellitus.
Fornes D, Gomez Ribot D, Heinecke F, Roberti SL, Capobianco E, Jawerbaum A
In a rat model of gestational diabetes mellitus (GDM) programmed in the offspring of neonatal streptozotocin-induced (nSTZ) diabetic rats, lipids are ...
Read More
Source: PubMed
Wiad. Lek.
Associations of irs-1 polymorphism with various components of the metabolic syndrome in hypertensive patients
Kochuieva M, Psarova V, Ruban L, Kyrychenko N, Alypova O, Matlai O, Shalimova A
The metabolic syndrome is one of the most discussed cross-disciplinary problems of modern medicine. Now there are various definitions and criteria of ...
Read More
Source: PubMed
Sci Transl Med
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
Wolska A, Lo L, Sviridov DO, Pourmousa M, Pryor M, Ghosh SS, Kakkar R, Davidson M, Wilson S, Pastor RW, Goldberg IJ, Basu D, Drake SK, Cougnoux A, Wu MJ, Neher SB, Freeman LA, Tang J, Amar M, Devalaraja M, Remaley AT
Recent genetic studies have established that hypertriglyceridemia (HTG) is causally related to cardiovascular disease, making it an active area for dr ...
Read More
Source: PubMed
Cas. Lek. Cesk.
Management of metabolic adverse effects of everolimus in patients with renal carcinoma.
Gregorová J, Holecková P, Žáková K
Everolimus is administered to patients with metastatic renal cell carcinoma in full daily dose of 10 mg or in reduced daily dose of 5 mg in case adver ...
Read More
Source: PubMed
Aging Clin Exp Res 2020 Feb 01
Prognostic value of non-alcoholic fatty liver disease in the elderly patients.
Tallarico V, Recinella G, Magalotti D, Muscari A, Zoli M, Bianchi G
Non-alcoholic fatty liver disease (NAFLD) is the liver manifestation of metabolic syndrome, a risk factor for mortality and cardiovascular morbidity, ...
Read More
Source: PubMed
J. Nutr. Biochem.
Maternal diets enriched in olive oil regulate lipid metabolism and levels of PPARs and their coactivators in the fetal liver in a rat model of gestational diabetes mellitus.
Fornes D, Gomez Ribot D, Heinecke F, Roberti SL, Capobianco E, Jawerbaum A
In a rat model of gestational diabetes mellitus (GDM) programmed in the offspring of neonatal streptozotocin-induced (nSTZ) diabetic rats, lipids are ...
Read More
Source: PubMed
Wiad. Lek.
Associations of irs-1 polymorphism with various components of the metabolic syndrome in hypertensive patients
Kochuieva M, Psarova V, Ruban L, Kyrychenko N, Alypova O, Matlai O, Shalimova A
The metabolic syndrome is one of the most discussed cross-disciplinary problems of modern medicine. Now there are various definitions and criteria of ...
Read More
Source: PubMed
Sci Transl Med
A dual apolipoprotein C-II mimetic-apolipoprotein C-III antagonist peptide lowers plasma triglycerides.
Wolska A, Lo L, Sviridov DO, Pourmousa M, Pryor M, Ghosh SS, Kakkar R, Davidson M, Wilson S, Pastor RW, Goldberg IJ, Basu D, Drake SK, Cougnoux A, Wu MJ, Neher SB, Freeman LA, Tang J, Amar M, Devalaraja M, Remaley AT
Recent genetic studies have established that hypertriglyceridemia (HTG) is causally related to cardiovascular disease, making it an active area for dr ...
Read More
Source: PubMed
Cas. Lek. Cesk.
Management of metabolic adverse effects of everolimus in patients with renal carcinoma.
Gregorová J, Holecková P, Žáková K
Everolimus is administered to patients with metastatic renal cell carcinoma in full daily dose of 10 mg or in reduced daily dose of 5 mg in case adver ...
Read More
Source: PubMed
